We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Accelr8 Announces Collaboration Agreement with Promega
News

Accelr8 Announces Collaboration Agreement with Promega

Accelr8 Announces Collaboration Agreement with Promega
News

Accelr8 Announces Collaboration Agreement with Promega

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Accelr8 Announces Collaboration Agreement with Promega "

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Accelr8 Technology Corporation has announced the signing of an agreement with Promega Corporation regarding Accelr8's proprietary OptiChem® surface chemistry for use in microarraying slides.

The agreement will allow for exploration of techniques in microarray research using Accelr8 and Promega technologies.
 
According to David Howson, Accelr8's president, “This agreement represents another event for Accelr8 in licensing out our technology components in the microarraying space.”

“We're gratified that Promega evaluated the alternatives and chose OptiChem because of its performance advantages,” said Howson.

“We are also pleased to be associated with Promega because of their well-deserved reputation for excellence.”

Accelr8's OptiChem coatings are designed to provide performance advantages that help to make OptiChem-coated slides an enabling component of next generation microarrays.

The ongoing revenues from licensing occur in parallel with Accelr8's primary business focus in developing the BACcelr8r™ rapid bacterial analysis system.

Advertisement